Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Pheochromocytoma
Trial Status:  Active
Results 1-25 of 47 for your search:
Start Over
Phenoxybenzamine Versus Doxazosin in PCC Patients
Phase: Phase IV
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PRESCRIPT2010.369, 2010:022417-25, NCT01379898
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230B2412, NCT01794793
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
Phase: Phase III
Type: Diagnostic
Status: Approved-not yet active
Age: Not specified
Sponsor: Other
Protocol IDs: H10-02695, NCT01373736
Randomized Phase III of PRRT Versus Interferon
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: IJBMNCASTOR, 2012-005545-20, NCT01860742
Gallium-68 DOTATOC for Management of Neuroendocrine Tumors
Phase: Phase III
Type: Diagnostic, Health services research
Status: Approved-not yet active
Age: Not specified
Sponsor: Other
Protocol IDs: 15-999, NCT02375464
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
Phase: Phase II, Phase I
Type: Tissue collection/Repository
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 93-102, NCT00579163
Interleukin 13 PE for Adults With Advanced Cancers
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 130046, 13-C-0046, NCT01766635
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 1
Sponsor: NCI
Protocol IDs: 04-148, MSKCC-04148, NCT00107289
Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SNIPP, NCT00843037
A Study Evaluating Ultratrace Iobenguane I 131 (MIBG) in Patients With Malignant Pheochromocytoma/Paraganglioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MIP-IB12B, NCT00874614
DOTA-TOC in Metastasized Neuroendocrine Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MAW002, NCT00978211
Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: EudraCT 2006-004748-22, NCT01203306
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 78,256, NCT01237457
First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IGR2010/1715, 2010-024621-20, MSI/A110356-31, NCT01371201
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
Phase: Phase II
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 130193, 13-C-0193, NCT01967537
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 140001, 14-C-0001, NCT01967576
Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies
Phase: Phase II
Type: Diagnostic
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: UCSF-DOTA-TOC, NCT02177773
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 25
Sponsor: NCI, Other
Protocol IDs: CDR0000257582, UIHC-200008086, NCI-V02-1710, 200008086, NCT00049023
Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
Phase: Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: UCL/12/0499, NCT01941849
Phase Ib Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2014-012-00CH1, NCT02267967
Diagnosis of Pheochromocytoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic
Status: Active
Age: Not specified
Sponsor: NICHD
Protocol IDs: 000093, 00-CH-0093, NCT00004847
Study of Adrenal Gland Tumors
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Status: Active
Age: 3 to 70
Sponsor: NICHD
Protocol IDs: 000160, 00-CH-0160, NCT00005927
Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Genetics, Screening
Status: Active
Age: 6 and over
Sponsor: Other
Protocol IDs: PHRC 04-01, NCT00188019
Adrenal Tumors - Pathogenesis and Therapy
Phase: No phase specified
Type: Diagnostic, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: Wue-Adrenal-Tumors-92/2002, NCT00669266
Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 08-451, NCT00672269
Start Over